| Literature DB >> 34988536 |
Sopheak Hem1,2, Veronica M Jarocki1,2, Dave J Baker3, Ian G Charles3,4, Barbara Drigo5, Sarah Aucote5, Erica Donner5, Delaney Burnard6, Michelle J Bauer6, Patrick N A Harris6, Ethan R Wyrsch1,2, Steven P Djordjevic1,2.
Abstract
Elizabethkingia species are ubiquitous in aquatic environments, colonize water systems in healthcare settings and are emerging opportunistic pathogens with reports surfacing in 25 countries across six continents. Elizabethkingia infections are challenging to treat, and case fatality rates are high. Chromosomal bla B , bla GOB and bla CME genes encoding carbapenemases and cephalosporinases are unique to Elizabethkingia spp. and reports of concomitant resistance to aminoglycosides, fluoroquinolones and sulfamethoxazole-trimethoprim are known. Here, we characterized whole-genome sequences of 94 Elizabethkingia isolates carrying multiple wide-spectrum metallo-β-lactamase (bla B and bla GOB) and extended-spectrum serine‑β-lactamase (bla CME) genes from Australian aquatic environments and performed comparative phylogenomic analyses against national clinical and international strains. qPCR was performed to quantify the levels of Elizabethkingia species in the source environments. Antibiotic MIC testing revealed significant resistance to carbapenems and cephalosporins but susceptibility to fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole. Phylogenetics show that three environmental E. anophelis isolates are closely related to E. anophelis from Australian clinical isolates (∼36 SNPs), and a new species, E. umeracha sp. novel, was discovered. Genomic signatures provide insight into potentially shared origins and a capacity to transfer mobile genetic elements with both national and international isolates.Entities:
Year: 2021 PMID: 34988536 PMCID: PMC8703026 DOI: 10.1016/j.crmicr.2021.100083
Source DB: PubMed Journal: Curr Res Microb Sci ISSN: 2666-5174
Gene targets, primers and probes used in this study.
| Gene target | Target organism | Primer/Probe ID | Fluorophore/Quencher | Final reaction conc (μM) | Product size (bp) | Primer sequence (5′−3′) | Reference |
|---|---|---|---|---|---|---|---|
| SECYF1_4 | 0.01 | GTTTTTACGTTCACGCTCATCTTGGT | |||||
| SECY R2 | 0.07 | 146 | AGTAAGCCTAAAAGCCCAGAAG | ||||
| SECYP2_5 | FAM/BHQ1 | 0.05 | TTGCAAGTATACAGAACCAAGGAGGAAGCAAG | ||||
| TIGR472_F7 | 0.1 | TTTAAACTGGATGTGGAAGATGCTGAT | |||||
| TIGR472_R1_2 | 0.05 | 90 | CCACTCTGGGGACTCTTCTACCTGT | ||||
| TIGR472_P3 | Quasar 670/BHQ3 | 0.05 | GCGTTATCTGGGAGCTGTAATTGAAGG | ||||
| TIGR1393F22 | 0.07 | CATGTGAAGGGGCGCTACTTATTGT | |||||
| T1393R3WT | 0.1 | 142 | TCAGGGTTTGCAGAAGGAAGGTC | ||||
| TIGR1393P1 | CalRed 610/BHQ1 | 0.02 | ACCTGGCTTTGGAAAATGACCTTACC |
Fig. 1Elizabethkingia spp., E. anophelis and E. meningoseptica average absolute abundance determined by qPCR analysis of total DNA extracted from filtered waters (site A, B, C and D). Data are expressed as log10 genes copies per mL, samples (n = 32). Asterisks denote: * = P < 0.05; ** = P < 0.01.
Aquatic environmental Elizabethkingia species (n = 94) identified by MALDI-TOF MS, Kraken2, Species Finder, and phylogenetic analysis.
| Species Identification | MALDI-TOF MS | Kraken2 | SpeciesFinder 2.0 | Phylogenetic characterization |
|---|---|---|---|---|
| 0 | 93 (99%) | 16 (17%) | 16 (17%) | |
| 11 (12%) | 0 | 0 | 0 | |
| 54 (57%) | 0 | 1 (1%) | 71 (76%) | |
| 0 | 1 (1%) | 77 (82%) | 0 | |
| 16 (17%) | 0 | 0 | 7 (7%) | |
| Non-Reliable Identification | 13 (14%) | 0 | 0 | 0 |
Also known as E. genomospecies 4.
Fig. 2Eizabethkingia phylogeny. Mid-point rooted maximum likelihood phylogenic tree and geographic data of Elizabethkingia species using Phylosift. Samples from this collection are coloured in purple.
E. umeracha sp. nov. is a separate species from E. bruuniana, as evidenced by ANIb, ANIm, GGDC, and 16S rRNA and rpoB sequence identity.
| Average values for seven | |||||
|---|---|---|---|---|---|
| ANIb(>95% cutoff) | ANIm(>95% cutoff) | Predicted DDH (>70% cutoff) | 16S rRNA (>99.5% cutoff) | rpoB(>97.7% cutoff) | |
| 76.70 ± 0.73 SD | 78.18 ± 0.57 SD | 49.23 ± 0.04 SD | 99.28 ± 0.17 SD | 97.59 ± 0 SD | |
| 76.41 ± 0.71 SD | 77.90 ± 0.65 SD | 45.18 ± 0.07 SD | 99.28 ± 0.17 SD | 97.59 ± 0 SD | |
| 76.57 ± 0.70 SD | 78.27 ± 0.65 SD | 49.17 ± 0.43 SD | 99.41 ± 0.18 SD | 97.62 ± 0 SD | |
Fig. 3Elizabethkingia pangenome. Pangenome analysis of 148 Elizabethkingia species from the Australian environment and clinical isolates alongside international strains.
Fig. 4Elizabethkingia pairwise genome distances. MDS illustrating pairwise genome distances calculated using Mash. Colored by species, shapes represent isolate source. Red areas are isolates from this collection.
Fig. 5Virulence factors of Elizabethkingia species. (A) Venn diagram of distribution of putative virulence factors across the three Elizabethkingia species identified in this collection. (B) MDS analysis of putative virulence factors identified in 148 Elizabethkingia isolates. Colored by species. Triangles = known pathogen; circles = ability to cause disease unknown. Red areas = isolates from this collection.
Fig. 6Elizabethkiniga blaGOB and blaB alleles. Phylogenetic trees of all Elizabethkingia blaB and blaGOB alleles. Left side is the tree of bla alleles and right side is the tree of bla alleles. Labels are colored in red for E. miricola, green for E. anophelis, blue for E. meningoceptica and orange for E. umeracha sp. nov. Connecting space between the trees links sequences from the same isolate. Available allele numbers are presented as colored strips.
MIC data of aquatic environmental Elizabethkingia isolates from South Australia against clinically relevant antimicrobials. Cells colors: red = resistant, yellow = intermediate, green = sensitive. blaB, blaGOB and blaCME alleles shown under isolate names; = variant = like.
| Antimicrobial | Range tested (µg/mL) | MIC 90 (µg/mL) | ER-QUAD-EK_14B-1L GOB-20 CME-1 | ER-QUAD-EK_56B-1L GOBVCME-1 | ER-QUAD-EK_18B-11 GOB20 CME-1 | ER-QUAD-EK_08BVGOBVCMEV | ER-QUAD-EK_09BVGOBVCMEV | ER-QUAD-EK_10BVGOBVCMEV | ER-QUAD-EK_21BVGOBVCMEV | ER-QUAD-EK_94B-6L GOB-25LCMEV | ER-QUAD-EK_64B-26L GOB-19L CMEV | ER-QUAD-EK_92B-26L GOB19L CMEV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin | 2–32 | > 32 | >32 | >32 | 32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 |
| Ampicillin | 2–32 | > 32 | >32 | >32 | 32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 |
| Amoxicillin/clavulanic acid | 4–128 | > 128 | 8 | 8 | 16 | 8 | 16 | 16 | 8 | 8 | 16 | 16 |
| Piperacillin/tazobactam | 1–64 | > 64 | <1 | <1 | <1 | <1 | <1 | 2 | <1 | 4 | 8 | 8 |
| Ampicillin/sulbactam | 8–128 | > 128 | 32 | 16 | 16 | 32 | 32 | 64 | 32 | 32 | 32 | 32 |
| Temocillin | 2–32 | > 32 | > 32 | 16 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 |
| Cephalexin | 4–64 | N/A | > 64 | > 64 | 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 |
| Cefazolin | 0.25–32 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 | > 32 | 32 | > 32 | > 32 |
| Cefuroxime | 1–16 | > 16 | >16 | >16 | 16 | >16 | >16 | >16 | >16 | >16 | > 16 | >16 |
| Cefoxitin | 8–256 | N/A | < 8 | < 8 | 16 | 32 | 32 | 32 | 32 | 16 | 32 | 32 |
| Cefotaxime | 0.03–8 | > 8 | > 8 | >8 | 8 | > 8 | 8 | 8 | 4 | 2 | 4 | 4 |
| Ceftazidime | 0.12–16 | > 16 | 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | 4 | > 16 | > 16 |
| Ceftriaxone | 0.03–4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | 2 | > 4 | > 4 |
| Cefiderocol | 0.03–32 | N/A | 8 | 4 | 8 | 4 | 4 | 4 | 1 | 1 | 4 | 8 |
| Cefepime | 0.06–16 | > 16 | >16 | 16 | 8 | 8 | 4 | 4 | 4 | 1 | 4 | 4 |
| Ceftaroline | 0.5–16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 |
| Ceftolozane/tazobactam | 0.5–16 | 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 |
| Meropenem | 0.015–32 | > 16 | 16 | 16 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Tebipenem | 0.03–8 | N/A | 8 | 4 | 8 | 8 | 8 | 8 | 4 | > 8 | 8 | 8 |
| Etrapenem | 0.015–4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 | > 4 |
| Aztreonam | 0.5–16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 | > 16 |
| Amikacin | 1–64 | 64 | 32 | 4 | 32 | 32 | 32 | 32 | 32 | 16 | 16 | 16 |
| Gentamicin | 0.25–16 | >16 | 8 | 2 | > 16 | 16 | 8 | 8 | 8 | 8 | 4 | 2 |
| Tobramycin | 0.015–64 | >16 | >64 | 32 | >64 | > 64 | 16 | 64 | 64 | 64 | 64 | 64 |
| Azithromycin | 4–64 | N/A | 8 | < 4 | 8 | < 4 | < 4 | < 4 | < 4 | < 4 | < 4 | < 4 |
| Ciprofloxacin | 0.015–4 | 2 | 1 | 0.12 | 0.25 | 0.25 | 0.25 | 0.12 | 0.06 | 0.5 | 0.25 | 0.25 |
| Levofloxacin | 0.06–8 | 1 | 0.25 | 0.125 | 0.25 | 0.125 | 0.125 | 0.125 | < 0.06 | 0.25 | 0.25 | 0.125 |
| Trimethoprim | 0.5–16 | N/A | 8 | 2 | 1 | < 0.5 | 2 | < 0.5 | < 0.5 | <0.5 | 2 | 2 |
| Trimethoprim/sulfamethoxazole | 0.12/2.38–32/608 | 2.38–152 | 8/152 | 1.0/19.0 | 0.5/9.5 | > 0.12/2.38 | 0.5/9.5 | 0.25/4.75 | <0.12/2.38 | <0.12/2.38 | 0.5/9.5 | 0.5/9.5 |
| Vancomycin | 0.12–32 | N/A | 8 | 8 | 8 | 4 | >32 | 4 | 4 | 8 | 8 | 8 |
| Teicoplanin | 2–64 | N/A | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 | > 64 |
| Minocycline | 0.25–16 | 1 | 0.5 | < 0.125 | 0.25 | 0.5 | 0.5 | 0.5 | < 0.125 | 0.5 | 0.25 | 0.5 |
| Doxycycline | 0.015–64 | > 64 | 2 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 0.25 | 0.5 | 1 | 1 |
| Tigecycline | 0.12–8 | 2 | 4 | 2 | 8 | 4 | 4 | 4 | 8 | 4 | 2 | 4 |
| Rifamicin | 0.12–32 | N/A | < 0.125 | < 0.125 | 0.25 | < 0.125 | 2 | < 0.125 | < 0.125 | < 0.125 | 0.25 | < 0.125 |
| Colistin | 0.25–8 | N/A | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 |
| Polymixin B | 0.25–8 | N/A | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 | > 8 |
| Chloramphenicol | 2–128 | >128 | 128 | 16 | 32 | 8 | 8 | 8 | 8 | 16 | 8 | 8 |